Document is current
Any future updates will be listed below
-
Authors
Lugogo, Njira L.
Soler, Xavier
Gon, Yasuhiro
Côté, Andréanne
Hilberg, Ole
Xia, Changming
Zhang, Yi
de Prado Gómez, Lucía
Rowe, Paul J.
Radwan, Amr
Jacob-Nara, Juby A.
Deniz, Yamo
Peters, Anju T.
-
Funding
Funding for this research was provided by:
Sanofi
Regeneron Pharmaceuticals
- License Information
-
More Information
Article History
Received: 19 June 2024
Accepted: 23 October 2024
First Online: 9 December 2024
Declarations
:
: Njira L. Lugogo reports consulting fees from Amgen, AstraZeneca, Avillion, Genentech, GSK, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, and Teva; honoraria for non-speakers bureau presentations from AstraZeneca and GSK; and travel support from AstraZeneca. Her institution received research support from Amgen, AstraZeneca, Avillion, Evidera, Gossamer Bio, Genentech, GSK, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, and Teva. She is an honorary faculty member of the Observational and Pragmatic Research Institute (OPRI) but does not receive compensation for this role. Xavier Soler, Changming Xia, Amr Radwan, and Yamo Deniz are Regeneron Pharmaceuticals Inc. employees and shareholders. Yasuhiro Gon reports research, speaker fees, and consultancy fees from AstraZeneca, GSK, Kyorin Pharmaceutical, Novartis, and Sanofi. Andréanne Coté is a member of the advisory boards for AstraZeneca, GSK, Sanofi, and Valeo; has received speaker fees from AstraZeneca, GSK, and Sanofi; and has received research support from GSK and AstraZeneca. Ole Hilberg is member of Sanofi advisory boards. Yi Zhang is a former Regeneron Pharmaceuticals Inc. employee and shareholder. Lucía de Prado Gómez, Paul J. Rowe, and Juby A. Jacob-Nara are Sanofi employees and may hold stock and/or stock options in the company. Anju T. Peters has received research and consulting support from AstraZeneca, GSK, Merck, Optinose, Regeneron Pharmaceuticals Inc., and Sanofi.
: RAPID is being conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice guideline, and applicable regulatory requirements. The RAPID protocol was reviewed and approved by the respective institutional review boards before patient recruitment. All patients provided written informed consent. For patients under the age of 18 years, both parental/legal guardian consent and patient assent were required.
